CHEK2 and breast cancer: Among the whole group, 184 (14.0%) patients had PV/LPVs; only 90 (48.9%) were in BRCA1 or BRCA2, while 94 (51.1%) others had pathogenic variants in other genes; mostly in APC, TP53, CHEK2 and PALB2. Mutation rates were higher among patients with positive family history (p=0.009); especially if they were 50 years or younger at the time of breast cancer diagnosis (p<0.001).